Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Primary Biliary Cholangitis Market Grown from 2024 to 2025?

The market size for primary biliary cholangitis has seen swift expansion in the recent past. An increase from $0.98 billion in 2024 to $1.09 billion in 2025 is anticipated, indicating a compound annual growth rate (CAGR) of 11.8%. The substantial growth in the earlier period is credited to heightened awareness of the disease, escalated healthcare expenditure worldwide, strategic alliances in healthcare segment, emphasis on patient advocacy, along with government commitments towards liver health.

What Growth Rate Is Anticipated for the Primary Biliary Cholangitis Market in the Coming Years?

In the coming years, the market size for primary biliary cholangitis is predicted to exhibit robust expansion, reaching $1.6 billion by 2029, at a compound annual growth rate (CAGR) of 9.9%. The projected growth in the forecast period is largely due to advancements in biomarker studies, international endeavors in managing rare diseases, amplified partnerships in clinical trials and a patient-focused approach in healthcare, along with escalating demand for liver transplants. Significant trends determining the growth during the forecast period encompass progress in biomarker studies, a heightened focus on non-invasive diagnostic procedures, research emphasis on immunomodulatory treatments, the introduction of artificial intelligence (ai), the inclusion of patient-generated outcomes in clinical trials, telemedicine’s role in patient care, concentration on combination treatments, and emerging therapies aimed at fibrosis.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13520&type=smp

Who Are the Leading Companies in the Primary Biliary Cholangitis Market?

Major companies operating in the primary biliary cholangitis market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck And Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Amgen Inc., Boehringer Ingelheim International GmbH., Gilead Sciences Inc., Vertex Pharmaceuticals, Dr. Reddy’s Laboratories Ltd., Amneal Pharmaceuticals LLC, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Intercept Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., CureVac N.V., Sangamo Therapeutics Inc., Calliditas Therapeutics AB, NGM Biopharmaceuticals Inc., Bluebird Bio Inc., Intellia Therapeutics Inc., Albireo Pharma Inc., TARGET PharmaSolutions Inc., Genfit S.A., Editas Medicine Inc., CymaBay Therapeutics Inc., Ascletis Pharma Inc.

What Are the Key Drivers of the Primary Biliary Cholangitis Market?

The rise in smoking rates is predicted to fuel the expansion of the primary biliary cholangitis market. The practice of smoking, characterized by the inhalation and exhalation of smoke from burned tobacco or other substances, is a recognized risk factor for various liver diseases, including PBC. Therefore, an increase in smoking prevalence can lead to a greater number of people seeking treatment for hepatic issues. For example, Statistics Canada documented that cigarette production in Canada enhanced by 2.2% in July 2023 compared to the previous month. Furthermore, the country witnessed a 2.6% surge in cigarette sales in June, touching 1.4 billion units, an increment from May. Thus, the ballooning smoking rates will propel the progress of the primary biliary cholangitis market. As for the primary biliary cholangitis market, a significant driver of its progression is the rise in liver cancer cases. Identified as a cancer type that initiates in liver cells, liver cancer’s relationship with primary biliary cholangitis is considerable due to the heightened risk of different malignancies, such as cholangiocarcinoma and hepatocellular carcinoma. The increasing prevalence of the disease and its probable complications boost the growth of the primary biliary cholangitis market. For instance, the American Cancer Society projected around 41,630 new liver cancer cases in the U.S in January 2024, with 28,000 in men and 13,630 in women. In addition, an estimated 29,840 individuals (19,120 men and 10,720 women) are expected to die from this malady. Hence, this spike in liver cancer cases is accelerating the expansion of the primary biliary cholangitis market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13520&type=smp

What Are the Key Market Segments in the Primary Biliary Cholangitis Industry?

The primary biliary cholangitis market covered in this report is segmented –

1) By Treatment Type: Drugs, Liver Transplantation

2) By Diagnosis: Imaging Tests, Magnetic Resonance Elastography (MRE), Magnetic Resonance Cholangiopancreatography (MRCP), Ultrasound, Fibroscan, Blood Tests, Cholesterol Test, Antibody Tests, Liver Tests, Other Diagnoses

3) By End-Users: Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Drugs: Ursodeoxycholic Acid (UDCA), Obeticholic Acid (OCA), Fibrates, Immunosuppressive Drugs, Other Targeted Therapies

2) By Liver Transplantation: Orthotopic Liver Transplantation (OLT), Living Donor Liver Transplantation, Hepatobiliary Surgery For Liver Transplant

What Are the Latest Trends in the Primary Biliary Cholangitis Market?

Businesses in the primary biliary cholangitis market are concentrating their efforts on the creation of advanced and tailored therapies like orphan drugs, which combine obeticholic acid (OCA) and bezafibrates to tackle primary biliary cholangitis (PBC), in order to achieve market exclusivity. The aim of coupling OCA and bezafibrate with orphan drug status is to establish a more complete and efficient strategy for managing PBC treatment, which might enhance the wellbeing of those affected by this uncommon ailment. For instance, in May 2023, the FDA granted orphan drug status to Intercept Pharmaceuticals, Inc., a biopharmaceutical firm based in the US, for the combination of obeticholic acid (OCA) and bezafibrate, a PPAR agonist, as a prospective treatment for primary biliary cholangitis, a progressive liver disease. Meanwhile, obeticholic acid is approved for PBC under the brand name Ocaliva in the US.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/primary-biliary-cholangitis-global-market-report

What Are the Key Regional Markets in the Primary Biliary Cholangitis Industry?

North America was the largest region in the primary biliary cholangitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13520

This Report Delivers Insight On:

1. How big is the primary biliary cholangitis market, and how is it changing globally?

2. Who are the major companies in the primary biliary cholangitis market, and how are they performing?

3. What are the key opportunities and risks in the primary biliary cholangitis market right now?

4. Which products or customer segments are growing the most in the primary biliary cholangitis market?

5. What factors are helping or slowing down the growth of the primary biliary cholangitis market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model